Literature DB >> 15498369

Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China.

Min Zhou1, Shao-guang Huang, Huan-ying Wan, Biao Li, Wei-wu Deng, Min Li.   

Abstract

BACKGROUND: There are many candidate genes for chronic obstructive pulmonary disease (COPD). Matrix metalloproteinase-9 (MMP-9) plays an essential role in tissue remodeling and repair associated with development of COPD. In this study we investigated the correlation between MMP-9 gene polymorphism and COPD susceptibility in the Han population of South China.
METHODS: We examined the frequency of polymorphic genotypes of the MMP-9 promoter (-1562C/T) in 100 COPD patients and 98 healthy smokers by restriction fragment length polymorphism.
RESULTS: The frequencies of polymorphic genotypes in promoters of MMP-9 were C/C 86%, C/T 14% in COPD group; and C/C 98%, C/T 2% in the control group. There were significant differences between the two groups (P < 0.01). The allele frequencies were also significantly different between the COPD group and the control group (C allele frequency: 93% vs 99%, T allele frequency: 7% vs 1%, P < 0.05 respectively).
CONCLUSION: The genetic polymorphism in promoters of MMP-9 gene is associated with the susceptibility to COPD in the Han population of South China.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498369

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  14 in total

Review 1.  Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.

Authors:  Kendra J Greenlee; Zena Werb; Farrah Kheradmand
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 2.  DNA sequence variations of metalloproteinases: their role in asthma and COPD.

Authors:  Fotis Sampsonas; Alexander Kaparianos; Dimosthenis Lykouras; Kiriakos Karkoulias; Kostas Spiropoulos
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 3.  National Emphysema Treatment Trial state of the art: genetics of emphysema.

Authors:  Craig P Hersh; Dawn L DeMeo; Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 4.  Updates on the COPD gene list.

Authors:  Yohan Bossé
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-18

5.  Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts.

Authors:  C C van Diemen; D S Postma; M Siedlinski; A Blokstra; H A Smit; H M Boezen
Journal:  Respir Res       Date:  2011-04-27

Review 6.  Genetics of chronic obstructive pulmonary disease.

Authors:  Carola Seifart; Alexandra Plagens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

7.  Chronic obstructive pulmonary disease: towards pharmacogenetics.

Authors:  Alice M Wood; See Ling Tan; Robert A Stockley
Journal:  Genome Med       Date:  2009-11-30       Impact factor: 11.117

8.  Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population.

Authors:  Imran Haq; Sally Chappell; Simon R Johnson; Juzer Lotya; Leslie Daly; Kevin Morgan; Tamar Guetta-Baranes; Josep Roca; Roberto Rabinovich; Ann B Millar; Seamas C Donnelly; Vera Keatings; William MacNee; Jan Stolk; Pieter S Hiemstra; Massimo Miniati; Simonetta Monti; Clare M O'Connor; Noor Kalsheker
Journal:  BMC Med Genet       Date:  2010-01-15       Impact factor: 2.103

9.  Matrix metalloproteinase-9 -1562C/T promoter polymorphism confers risk for COPD: a meta-analysis.

Authors:  Lei Chen; Tao Wang; Lian Liu; Yongchun Shen; Chun Wan; Fuqiang Wen
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  Genetic polymorphism of matrix metalloproteinase family and chronic obstructive pulmonary disease susceptibility: a meta-analysis.

Authors:  Hongbin Zhou; Yinfang Wu; Yan Jin; Jiesen Zhou; Chao Zhang; Luanqing Che; Jiyong Jing; Zhihua Chen; Wen Li; Huahao Shen
Journal:  Sci Rep       Date:  2013-10-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.